Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00681343 · ClinicalTrials.gov registry record · Phase 4
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 38
- Enrollment target
NCT00681343 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 38 participants.
The verdict
NCT00681343, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 38 participants
- Enrollment target
Study Summary
To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression
Interventions
- DRUG Thymoglobulin
- DRUG Daclizumab
- DRUG Campath-1H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00681343
The ClinicalTrials.gov registry entry for NCT00681343 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Thymoglobulin is the first listed.
NCT00681343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00681343 about?
NCT00681343 is a clinical study titled "Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation". To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression
What is the current status of trial NCT00681343?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 2002-09. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00681343?
The interventions under investigation include: Thymoglobulin (DRUG), Daclizumab (DRUG), Campath-1H (DRUG).
Who is sponsoring clinical trial NCT00681343?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.